Collecting and storing tissue samples from melanoma patients
Analysis of the Tumor Microenvironment and Immune Response in Malignant Melanoma
Ohio State University Comprehensive Cancer Center · NCT04567706
This study is collecting blood and tumor samples from melanoma patients and healthy people to help researchers learn more about melanoma and find better ways to treat it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Ohio State University Comprehensive Cancer Center (other) |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Columbus, Ohio) |
| Trial ID | NCT04567706 on ClinicalTrials.gov |
What this trial studies
This study collects and stores blood and tumor samples from patients diagnosed with malignant melanoma, as well as healthy individuals, to better understand the causes and behavior of melanoma tumors. The primary objective is to facilitate research aimed at identifying new prognostic markers and potential therapeutic options for melanoma. Blood samples will be collected at various stages of the patient's treatment and follow-up, while tissue samples may be obtained during standard medical procedures. This biorepository aims to support future research that could lead to advancements in melanoma diagnosis and treatment.
Who should consider this trial
Good fit: Ideal candidates include patients with malignant melanoma at any stage and healthy individuals willing to participate.
Not a fit: Patients who are incarcerated will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment options for patients with malignant melanoma.
How similar studies have performed: Other studies collecting biospecimens for melanoma research have shown promise in identifying new treatment strategies and prognostic markers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with malignant melanoma or personal history of melanoma * Normal donors * Informed consent can be obtained * Patients with any stage of malignant melanoma Exclusion Criteria: * Incarcerated individuals will be excluded from this protocol
Where this trial is running
Columbus, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (RECRUITING)
Study contacts
- Principal investigator: William E Carson, MD — Ohio State University Comprehensive Cancer Center
- Study coordinator: The Ohio State University Comprehensive Cancer Center
- Email: OSUCCCClinicaltrials@osumc.edu
- Phone: 800-293-5066
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Melanoma